Good for ↑
Curium is in advanced talks to acquire radiopharma company Lantheus Holdings in a deal valued at approximately $7 billion, with an announcement potentially coming within days, per people familiar with the matter.
Source: Bloomberg ↗
An imminent ~$7B acquisition announcement for LNTH represents a hard M&A catalyst. The stock should re-rate sharply toward the deal price upon announcement. With a deal expected in days, the trade window is extremely short and the catalyst is specific and named.
Market has not priced in this deal — it is based on unnamed sources and has not been officially announced, so LNTH trades at pre-deal levels.
Why that may be wrong
Unnamed-sources M&A reporting from credible outlets (Bloomberg-style) historically precedes official announcements by 1-3 days; the stock typically gaps up 30-60% on the official announcement, meaning pre-announcement price still embeds significant discount.
Deal falls apart before announcement — observable if LNTH fails to gap up within 5 trading days or if a denial is issued by either party; a competing bidder or regulatory block could also derail the premium.
If Curium is private and financing conditions tighten (10Y yield already at 4.64%), deal financing could collapse, sending LNTH back to pre-rumor levels — watch for any credit market stress signals.
When RayzeBio was acquired by Bristol-Myers Squibb in January 2024 for ~$4.1B, the stock surged ~85% on announcement day. Radiopharma M&A premiums have consistently run 50-100% above pre-announcement prices in recent years.
No comments yet.
Sign in to comment
Earlier connections in the same sector that share a theme with this one.